Evaluation of the Benefit and Safety of Localized Tissue Hydration in the Management of Chronic Low Back Pain

Last updated: March 24, 2025
Sponsor: GCS Ramsay Santé pour l'Enseignement et la Recherche
Overall Status: Active - Recruiting

Phase

2

Condition

Chronic Pain

Treatment

Sodium Chloride injection

Clinical Study ID

NCT06471998
2024-510625-25-00
  • Ages > 18
  • All Genders

Study Summary

The purpose of this study is to evaluate the benefit of Localized Tissue Hydration associated with standard management of chronic common low back pain, in terms of improvement in the numerical verbal scale score at 6 months.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patient 18 years of age or older ;

  • Patient with chronic, non-operated low-back pain operated for more than 3 months (verbal numerical scale ≥ 5);

  • Chronic common lumbago not requiring surgical management surgical ;

  • Lumbar MRI performed as part of routine care and available available for theinclusion visit;

  • For women of childbearing age, use of a highly effective contraceptive method;

  • Patient affiliated to a French health insurance scheme;

  • Patient has signed an informed consent form.

Exclusion

Exclusion Criteria:

  • Pregnant or breast-feeding woman;

  • Patient in accident at work ;

  • Patient with radicular syndrome;

  • Contraindication to magnetic resonance imaging or CT scan;

  • Severe cases of hydric inflation and hydrosodic retention, particularly in cases of :

  • Decompensated heart failure;

  • Acute renal failure with oliguria or anuria;

  • Decompensated liver failure;

  • Pre-eclampsia/eclampsia.

  • Hypochloremia ;

  • Hypernatremia ;

  • Patients of legal age subject to legal protection, guardianship, curatorship ordeprived of liberty by judicial or administrative decision;

  • Patient hospitalized without consent;

  • Patient unable to answer a questionnaire;

  • Patients who do not understand or speak French.

Exclusion period for inclusion in another study :

Included patients will not be allowed to participate in another interventional study during the entire follow-up period. The exclusion period is 8.5 months.

Study Design

Total Participants: 29
Treatment Group(s): 1
Primary Treatment: Sodium Chloride injection
Phase: 2
Study Start date:
February 28, 2025
Estimated Completion Date:
September 30, 2025

Study Description

This is a proof-of-concept, single-center, prospective, interventional, non-randomized Phase II study designed to evaluate the benefit of 0.9% sodium chloride Localized Tissue Hydration in patients with chronic common low back pain.

The study corresponds to a clinical trial of a medicinal product in compliance with Regulation (EU) n°536/2014.

The study population is composed of patients suffering from chronic common low back pain for more than 3 months with a numerical verbal scale ≥ 5.

Patients will receive a localized subcutaneous injection of 0.9% sodium chloride over 10 sessions (1 session per week), combined with standard management including stage I and II analgesics and physiotherapy in accordance with the recommendations of the French National Authority for Health.

Connect with a study center

  • Hôpital Privé Clairval

    Marseille, 13009
    France

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.